Moreover, BRAF inhibition (BRAFi)-resistant melanoma cells were shown to present with deregulation of the fatty acid synthase (FASN) [10], which was proposed as a metabolic target for melanoma, prostate, and breast cancer treatment [11]. Here, FASN is linked to melanoma.